Tenofovir
- Generic Name
- Tenofovir
- Brand Names
- Vemlidy, Tenofovir disoproxil Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C9H14N5O4P
- CAS Number
- 147127-20-6
- Unique Ingredient Identifier
- W4HFE001U5
- Background
Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate. In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in the form of tenofovir disoproxil and tenofovir alafenamide in order to obtain oral bioavailability.
- Indication
Tenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus.
To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, tenofovir alafenamide and tenofovir disoproxil.
- Associated Conditions
- -
- Associated Therapies
- -
Tenofovir Disoproxil Fumarate to Treat Pediatric HIV
- Conditions
- HIV Infection
- First Posted Date
- 2001-10-11
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00024986
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.